(ASRT) Assertio Holdings, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ASRT) Assertio Holdings, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Assertio Holdings, Inc. BCG Matrix helps you quickly see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to access the complete ready-to-use report.
Stars
No clear Star
Assertio Holdings, Inc. shows no clear Star at end-2025: its 5 marketed products are still mostly niche and mature, not a high-growth, high-share leader. The mix points more to cash generation and turnaround economics than to a true Star asset. In BCG terms, the portfolio lacks a standout product with strong growth momentum and dominant share.
Commercial-stage portfolio
Assertio Holdings is built on marketed brands, not a deep launch pipeline, so it looks more like a brand manager than a classic Star candidate. Stars need fast market growth plus strong share, and Assertio’s model leans on mature assets such as Indocin and Sympazan rather than many new growth bets. That makes this business better fit Cash Cows or Dogs than Stars.
Neurology focus
CAMBIA gives Assertio Holdings, Inc. a neurology-facing asset in migraine, a recurring-treatment market that affects about 1 billion people worldwide. Still, the prompt does not show Assertio as the category leader, so this looks like a growth option, not a proven Star. If CAMBIA can win more refill volume, the brand could scale faster.
Pain and inflammation focus
Most of Assertio Holdings, Inc.'s revenue still comes from pain and inflammation brands, a mature space with heavy generic and branded competition. In a BCG view, that mix fits Cash Cows more than Stars unless growth and share re-accelerate. The key test is whether newer specialty-care assets can outgrow a flat market.
- Core market: mature and crowded
- Growth needs clear share gains
- Current mix leans Cash Cow
5 marketed products
Assertio Holdings, Inc.'s portfolio is concentrated in 5 marketed products, which can support steadier cash flow but leaves limited room for a true breakout Star. A Star needs both scale and fast share gains, and that is not clear here given the narrow brand base and lack of a dominant high-growth asset.
- 5 brands drive the portfolio.
- Cash flow can stay more stable.
- Growth upside looks limited.
- No clear Star emerges.
Assertio’s 2025 Portfolio: Cash Generation, Not a Star Growth Story
Assertio Holdings, Inc. shows no clear Star in 2025. Its 5 marketed products are mostly mature and niche, so the portfolio fits cash generation more than fast growth.
| Star test | Assertio Holdings, Inc. |
|---|---|
| Market growth | Low |
| Share leadership | Not clear |
| Marketed products | 5 |
| BCG view | No Star |
What is included in the product
Detailed Word Document
BCG Matrix overview of Assertio Holdings, Inc.’s portfolio, highlighting growth, cash generation, and divestment priorities.
Editable Excel File
Clean BCG Matrix for Assertio Holdings, Inc. that quickly clarifies portfolio pain points for faster decisions
Reference Sources
Provides a clear source trail for Assertio Holdings, Inc., boosting credibility and helping decision-makers verify key claims fast.
Cash Cows
INDOCIN oral solution
INDOCIN oral solution is a branded indomethacin used for rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. As a legacy product in long-settled indications, it fits a mature-market profile, which is classic Cash Cow territory if Assertio Holdings, Inc. keeps share and pricing intact. Its value is steady cash generation, not high growth.
INDOCIN suppository
INDOCIN suppository is the same indomethacin franchise in a second dosage form, and indomethacin has been on the market since 1963. The segment is mature and well understood, so promotion spend is usually lighter than for growth brands. That setup can still throw off steady cash flow from branded access and repeat prescribing.
SPRIX nasal spray
SPRIX is ketorolac nasal spray for short-term moderate to moderately severe pain, so it has clear differentiation but sits in a low-growth pain market. That fits a Cash Cow profile: stable demand, limited expansion, and repeatable cash flow. FDA labeling caps use at 5 days, which keeps the product niche but can support steady monetization for Assertio Holdings, Inc.
Mature NSAID franchise
INDOCIN, SPRIX, and Zipsor sit in established NSAID pain care, where demand is steady, not fast-growing. That makes this line fit the Cash Cow label: mature products, branded pricing power, and repeat use in a large, stable market. INDOCIN alone has been on the US market since 1965, which is classic late-life franchise behavior.
- Stable NSAID demand
- Branded, recurring revenue
- Low growth, high maturity
Legacy branded revenue
Assertio Holdings, Inc. fits a Cash Cow profile because its value comes from legacy branded prescription products, not heavy new-drug spend. Mature brands can keep generating cash with limited launch and R&D needs, so free cash flow can stay strong even when growth is slow. That is why BCG treats established portfolios as cash generators, not expansion engines.
- Legacy brands drive most value
- Low reinvestment supports cash flow
- Mature products suit Cash Cows
Assertio's Mature Pain Brands Keep Cash Flow Steady
Assertio Holdings, Inc. cash cows are mature, branded pain products with steady repeat use and low reinvestment needs. INDOCIN dates to 1963 and SPRIX carries a 5-day FDA limit, both signs of a slow-growth, cash-generating portfolio.
| Brand | Signal |
|---|---|
| INDOCIN | 1963 launch |
| SPRIX | 5-day use cap |
Preview Before You Purchase
Assertio Holdings, Inc. Reference Sources
The Assertio Holdings, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no placeholders, watermarks, or demo sections—just the full, ready-to-use report. Download it instantly and use it for analysis, planning, or presentation.
Dogs
Zipsor capsules
Zipsor capsules are diclofenac potassium for mild to moderate acute pain. In a crowded NSAID market, with many low-cost generics and no clear growth driver, Zipsor fits the Dogs quadrant: low share, low growth, and limited strategic upside for Assertio Holdings, Inc.
Acute pain niche
Acute pain is a weak fit for Assertio Holdings, Inc. in BCG terms because the market is crowded, short-use, and price-sensitive, so a small branded product has little room to grow. It faces many substitutes, from OTC NSAIDs to generics and prescription options, which keeps margins under pressure. If share stays small and scale never improves, this niche fits the "Dog" profile.
Generic-pressured NSAID space
The generic-pressured NSAID space is a classic Dog for Assertio Holdings, Inc.: branded products face heavy price erosion once generics and OTC substitutes crowd the shelf, so margins stay thin unless a drug owns clear scale or loyalty.
That is the core risk for Zipsor, a low-share diclofenac NSAID, because small volume spreads fixed costs across too few prescriptions and weakens returns.
With NSAID demand mature and commoditized, even modest rebate pressure or payer step-editing can quickly squeeze profit.
Small-share pain brand
Zipsor is a specialty brand, not a broad market leader, so it fits the Dog profile in Assertio Holdings, Inc.’s BCG Matrix. In a mature pain market, low share means weak scale and limited upside, so heavy growth spend usually does not make sense. The right move is to manage cash, not chase share.
- Specialty niche, not a leader
- Low share in a mature market
- Cash focus beats growth spend
Harvest candidate
Zipsor looks like a Dogs-style holding for Assertio Holdings, Inc.: a mature 25 mg diclofenac potassium pain product, better suited to cash harvest than big reinvestment. In a BCG Matrix, the goal is to protect margin and take cash, not chase heavy scale-up. That fits a value-preservation playbook.
- Cash extraction, not expansion
- Preserve value, limit capex
- Mature, low-growth product
Zipsor: a cash-harvest dog in a crowded NSAID market
Zipsor 25 mg stays a Dogs asset for Assertio Holdings, Inc.: a small, mature NSAID brand in a crowded, price-led market with many OTC and generic substitutes. Low share and thin scale limit upside, so the best use is cash harvest, not growth spend.
| Item | Signal |
|---|---|
| Zipsor | Dog |
| Market | Mature NSAID |
| Fit | Cash focus |
Question Marks
CAMBIA migraine NSAID
CAMBIA (diclofenac potassium) treats acute migraine symptoms, and migraine remains a large, recurring market, with about 1 in 7 people worldwide affected. That gives CAMBIA room to grow if promotion and access improve. But the brand does not show clear market dominance here, so it fits Question Mark in the BCG Matrix.
Otrexup methotrexate auto-injector
Otrexup is Assertio Holdings, Inc.'s single-dose methotrexate auto-injector for severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis. The delivery form is clearly differentiated, and these are high-need diseases, but it still looks like a Question Mark because there is no clear proof of strong share or scale. Assertio’s 2025/2026 filings are needed to confirm revenue traction and market position.
Migraine treatment market
Migraine is a recurring, high-need market: the Global Burden of Disease study estimated about 1.1 billion people lived with migraine in 2021. That supports steady demand and room for branded specialty products. For Assertio Holdings, Inc., this is a Question Mark: it can grow only if it wins share fast, or it can slide toward Dog status.
Rheumatoid arthritis and JIA market
Rheumatoid arthritis and pediatric JIA are chronic, long-duration therapies, with RA affecting about 1.3 million U.S. adults and JIA about 300,000 U.S. children. Otrexup’s auto-injector gives Assertio Holdings, Inc. a convenience edge versus manual methotrexate, but the franchise still needs much higher share and repeat use to justify Star status.
- Long-duration use supports steady demand.
- Auto-injection improves dosing convenience.
- Share gains must outpace rivals.
- Without scale, it stays a Question Mark.
Specialty delivery formats
Assertio Holdings, Inc.’s oral solution, suppository, nasal spray, and auto-injector formats can help products fit niche care needs and stand out in small therapeutic lanes. In BCG terms, they stay Question Marks until share scales and repeat demand proves the model. Their value is real, but the growth case still needs stronger commercial traction.
- Differentiate in narrow therapy areas
- Support easier patient use
- Need scale to exit Question Mark
Big Markets, But Still Fighting for Share
Assertio Holdings, Inc.’s Question Mark products sit in large but crowded niches: CAMBIA in migraine and Otrexup in rheumatoid arthritis and JIA. Demand is real, but share is not yet strong enough to call them Stars, so growth depends on faster adoption and better access.
| Product | Market signal | BCG view |
|---|---|---|
| CAMBIA | ~1.1B migraine cases worldwide (2021) | Question Mark |
| Otrexup | RA ~1.3M U.S. adults; JIA ~300K U.S. children | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.